Efficacy of polyphenolic ingredients of Chinese herbs in treating dyslipidemia of metabolic syndromes

Journal of Chinese Integrative Medicine

Volumn 12, Issue 3, 2014, Pages 135-146

  Yao, Zemin ^a,b   Zhang, Li ^b   Ji, Guang ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Chinese herbal; Drugs; Dyslipidemias; Metabolic syndromes; Reviews

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ABC TRANSPORTER A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BERBERINE; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER; CHYLOMICRON; CURCUMIN; FLAVONOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; JANUS KINASE; KEXIN TYPE 9; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDES AND PROTEINS; POLYPHENOL DERIVATIVE; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIOXIDANT ACTIVITY; AUTOSOMAL RECESSIVE DISORDER; CHINESE HERB; CUSHING SYNDROME; DRUG EFFECT; DYSLIPIDEMIA; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DRUGS, CHINESE HERBAL; DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; LIPOPROTEINS; METABOLIC SYNDROME X; POLYPHENOLS;

EID: 84901461660     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2095-4964(14)60023-6     Document Type: Review

References (89)

1. Graham MJ, Lee RG, Bell TA, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burkey J, Crooke ST, Crooke RM. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013; 112(11): 1479-1490.
2. Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis. 2013; 227(1): 125-129.
3. Hussain MM, Rava P, Pan X, Dai K, Dougan SK, Iqbal J, Lazare F, Khatun I. Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism. Curr Opin Lipidol. 2008; 19(3): 277-284.
4. Aegerion Pharmaceuticals, Inc. FDA approves Aegerion Pharmaceuticals' JUXTAPIDTM (lomitapide) Capsules for homozygous familial hypercholesterolemia (HoFH). (2012-12-24) [2013-6-15]. http://ir.aegerion.com/releasedetail.cfm?ReleaseID=728650.
5. Sundaram M, Yao Z. Intrahepatic role of exchangeable apo-lipoproteins in lipoprotein assembly and secretion. Arterioscler Thromb Vasc Biol. 2012; 32(5): 1073-1078.
6. Ya o Z, Wang Y. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol. 2012; 23(3): 206-212.
7. Furtado JD, Wedel MK, Sacks FM. Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins. J Lipid Res. 2012; 53(4): 784-791.
8. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercho-lesterolemia. Nat Clin Pract Cardiovasc Med. 2008; 5(8): 497-505.
9. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009; 29(4): 431-438.
10. Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res. 2009; 50(Suppl): S15-S27.
11. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004; 279(48): 50630-50638.
12. Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008; 49(6): 1152-1156.
13. Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A. 2009; 106(24): 9546-9547.
14. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005; 115(5): 1333-1342.
15. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007; 117(8): 2216-2224.
16. Brooks R, Jennions MD. The dark side of sexual selection. Trends Ecol Evol. 1999; 14(9): 336-337.
17. Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, Gotz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani MF, Rothe G, Lackner KJ, Chimini G, Schmitz G. Transport of lipids from Golgi to plasma membrane is defective in tangier disease patients and Abc1-defcient mice. Nat Genet. 2000; 24(2): 192-196.
18. Knox R. Merck: niacin drug mix fails to prevent heart attacks, strokes. (2012-12-20) [2013-6-20]. http://www.npr.org/blogs/health/2012/12/20/167713438/merck-undercuts-popular-notion-that-niacin-prevents-heart-attacks.
19. Klett EL, Patel S. Genetic defenses against noncholesterol sterols. Curr Opin Lipidol. 2003; 14(4): 341-345.
20. Altmann SW, Davis HR Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004; 303(5661): 1201-1204.
21. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr., Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill K A, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005; 102(23): 8132-8137.
22. Grigore L, Norata GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag. 2008; 4(2): 267-278.
23. Burnett JR, Watts GF. MTP inhibition as a treatment for dyslipidemias: time to deliver or empty promises? Expert Opin Ther Targets. 2007; 11(2): 181-189.
24. Hesse D, Radloff K, Jaschke A, Lagerpusch M, Chung B, Tailleux A, Staels B, Schurmann A. Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly. J Lipid Res. 2014; 55(1): 41-52.
25. Jones B, Jones EL, Bonney SA, Patel HN, Mensenkamp AR, Eichenbaum-Voline S, Rudling M, Myrdal U, Annesi G, Naik S, Meadows N, Quattrone A, Islam SA, Naoumova RP, Angelin B, Infante R, Levy E, Roy CC, Freemont PS, Scott J, Shoulders CC. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet. 2003; 34(1): 29-31.
26. Young SG, Davies BS, Voss CV, Gin P, Weinstein MM, Tontonoz P, Reue K, Bensadoun A, Fong LG, Beigneux AP. GPIHBP1, an endothelial cell transporter for lipoprotein lipase. J Lipid Res. 2011; 52(11): 1869-1884.
27. Brunzell JD, Deeb S. Familial lipoprotein lipase deficiency, apoCII deficiency, and hepatic lipase defciency. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill Medical Publishing Division. 2001: 2789-2816.
28. Sundaram M, Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond). 2010; 7: 35.
29. Adiels M, Borén J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2005; 25(8): 1697-1703.
30. Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, Packard CJ, Caslake MJ. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis. 2004; 176(1): 49-56.
31. Wu X, Chen K, Williams KJ. The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia. Curr Opin Lipidol. 2012; 23(4): 334-344.
32. Lafontan M, Langin D. Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res. 2009; 48(5): 275-297.
33. Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013; 27(1): 1-13.
34. Yao Z, Zhou H, Figeys D, Wang Y, Sundaram M. Microsome-associated lumenal lipid droplets in the regulation of lipoprotein secretion. Curr Opin Lipidol. 2013; 24(2): 160-170.
35. Myers MG Jr., Heymsfeld SB, Haft C, Kahn BB, Laughlin M, Leibel RL, Tschop MH, Yanovski JA. Challenges and opportunities of defining clinical leptin resistance. Cell Metab. 2012; 15(2): 150-156.
36. Löllmann B, Grüninger S, Stricker-Krongrad A, Chiesi M. Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. Biochem Biophys Res Commun. 1997; 238(2): 648-652.
37. Choi SM, Tucker DF, Gross DN, Easton RM, DiPilato LM, Dean AS, Monks BR, Birnbaum MJ. Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol Cell Biol. 2010; 30(21): 5009-5020.
38. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008; 7(2): 95-96.
39. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest. 2008; 118(6): 2347-2364.
40. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest. 2004; 114(10): 1493-1503.
41. Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem. 1997; 272(49): 30693-30702.
42. Carvalheira JB, Torsoni MA, Ueno M, Amaral ME, Araujo EP, Velloso LA, Gontijo JA, Saad MJ. Cross-talk between the insulin and leptin signaling systems in rat hypothalamus. Obes Res. 2005; 13(1): 48-57.
43. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond). 1999; 96(5): 513-523.
44. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001; 294(5549): 2166-2170.
45. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013; 6(4): 295-308.
46. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB. Berberine, a natural plant product, activates AMP-activated protein kinase with benefcial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006; 55(8): 2256-2264.
47. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JB. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009; 296(4): E812-E819.
48. Chang XX, Yan HM, Xu Q, Xia MF, Bian H, Zhu TF, Gao X. The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. Lipids Health Dis. 2012; 11: 86.
49. Hu Y, Davies GE. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia. 2010; 81(5): 358-366.
50. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004; 10(12): 1344-1351.
51. Zhou JY, Zhou SW, Zhang KB, Tang JL, Guang LX, Ying Y, Xu Y, Zhang L, Li DD. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull. 2008; 31(6): 1169-1176.
52. Wu N, Sarna LK, Siow YL, O K. Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocys-teinemia. Am J Physiol Regul Integr Comp Physiol. 2011; 300(3): R635-R643.
53. Yin J, Xing H, Ye J. Effcacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008; 57(5): 712-717.
54. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008; 93(7): 2559-2565.
55. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010; 59(2): 285-292.
56. Derosa G, D'Angelo A, Bonaventura A, Bianchi L, Romano D, Maffoli P. Effects of berberine on lipid profle in subjects with low cardiovascular risk. Expert Opin Biol Ther. 2013; 13(4): 475-482.
57. Trimarco B, Benvenuti C, Rozza F, Cimmino CS, Giudice R, Crispo S. Clinical evidence of effcacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab. 2011; 4(2): 133-139.
58. Ge Y, Zhang Y, Li R, Chen W, Li Y, Chen G. Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes. Int J Biol Sci. 2011; 7(5): 673-684.
59. Zhao HL, Sui Y, Qiao CF, Yip KY, Leung RK, Tsui SK, Lee HM, Wong HK, Zhu X, Siu JJ, He L, Guan J, Liu LZ, Xu HX, Tong PC, Chan JC. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes. 2012; 61(4): 933-943.
60. Zhou J, Zhou S. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol. 2010; 649(1-3): 390-397.
61. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009; 284(42): 28885-28895.
62. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 2005; 25(10): 2170-2176.
63. Lee TS, Pan CC, Peng CC, Kou YR, Chen CY, Ching LC, Tsai TH, Chen SF, Lyu PC, Shyue SK. Anti-atherogenic effect of berberine on LXRα-ABCA1-dependent cholesterol effux in macrophages. J Cell Biochem. 2010; 111(1): 104-110.
64. Li GS, Liu XH, Zhu H, Huang L, Liu YL, Ma CM, Qin C. Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver X receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters. Biol Pharm Bull. 2011; 34(5): 644-654.
65. Chen C, Zhang Y, Huang C. Berberine inhibits PTP1B activity and mimics insulin action. Biochem Biophys Res Commun. 2010; 397(3): 543-547.
66. Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, Nan FJ, Li J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta. 2006; 1760(11): 1682-1689.
67. Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D, Gao X. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res. 2010; 51(9): 2504-2515.
68. Zhou Y, Cao S, Wang Y, Xu P, Jian K, Bin W, Qiu F, Kang N. Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells. Fitoterapia. 2014; 92: 230-237.
69. Xie W, Gu D, Li J, Cui K, Zhang Y. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One. 2011; 6(9): e24520.
70. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z, Zhang Y, Li X, Ning G, Zhao L. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012; 7(8): e42529.
71. Koo SI, Noh SK. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. J Nutr Biochem. 2007; 18(3): 179-183.
72. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, Elis A, Aviram M. Reduced progression of atherosclerosis in apolipoprotein E-defcient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol. 1997; 17(11): 2744-2752.
73. Allister EM, Borradaile NM, Edwards J Y, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus favonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes. 2005; 54(6): 1676-1683.
74. Borradaile NM, de Dreu LE, Huff MW. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus favonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes. 2003; 52(10): 2554-2561.
75. Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes. 2009; 58(10): 2198-2210.
76. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. 2008; 47(5): 1437-1445.
77. Casaschi A, Wang Q, Dang K, Richards A, Theriault A. Intestinal apolipoprotein B secretion is inhibited by the favonoid quercetin: potential role of microsomal triglyceride transfer protein and diacylglycerol acyltransferase. Lipids. 2002; 37(7): 647-652.
78. Kurowska EM, Manthey JA, Casaschi A, Theriault AG. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyfavone, tangeretin. Lipids. 2004; 39(2): 143-151.
79. Jang EM, Choi MS, Jung UJ, Kim MJ, Kim HJ, Jeon SM, Shin SK, Seong CN, Lee MK. Benefcial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism. 2008; 57(11): 1576-1583.
80. Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM, Lee MK. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res. 2008; 52(9): 995-1004.
81. Li JM, Li YC, Kong LD, Hu QH. Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyc-eridemia and hepatic steatosis in fructose-fed rats. Hepatology. 2010; 51(5): 1555-1566.
82. Kang OH, Kim SB, Seo YS, Joung DK, Mun SH, Choi JG, Lee YM, Kang DG, Lee HS, Kwon DY. Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells. Eur Rev Med Pharmacol Sci. 2013; 17(19): 2578-2586.
83. Kim M, Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Pract. 2010; 4(3): 191-195.
84. Manjunatha H, Srinivasan K. Hypolipidemic and antioxidant effects of dietary curcumin and capsaicin in induced hyper-cholesterolemic rats. Lipids. 2007; 42(12): 1133-1142.
85. Martínez-Morúa A, Soto-Urquieta MG, Franco-Robles E, Zúñiga-Trujillo I, Campos-Cervantes A, Pérez-Vázquez V, Ramírez-Emiliano J. Curcumin decreases oxidative stress in mitochondria isolated from liver and kidneys of high-fat diet-induced obese mice. J Asian Nat Prod Res. 2013; 15(8): 905-915.
86. Hu GX, Lin H, Lian QQ, Zhou SH, Guo J, Zhou HY, Chu Y, Ge RS. Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: improving lipid profles in high-fat-diet-treated rats. PLoS One. 2013; 8(3): e49976.
87. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, Ernie S. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones. 2008; 40(4): 201-210.
88. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013; 15(1): 195-218.
89. Sahebkar A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr. 2013 Sep 25. Epub ahead of print.